Competition Commission probing price of Covid-19 treatment remdesivir
Activists and researchers complain about the charge for treatment imported from the US
The Competition Commission is investigating the price of US pharmaceutical manufacturer Gilead Science’s coronavirus treatment remdesivir and prices charged by generic firms to which it granted manufacturing licences after a complaint by activists and researchers.
Commission spokesperson Makunga Siyabulela said on Monday that the organisation received a request from non-profit organisation the Health Justice Initiative (HJI) and Wits research unit Ezintsha to examine the price of remdesivir. “It is ... currently under investigation and remedies are likely to be behavioural and/or an administrative penalty, if there is a finding of a contravention,” he said...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.